Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000071.xml
Semin Neurol 2013; 33(03): 307-308
DOI: 10.1055/s-0033-1354604
DOI: 10.1055/s-0033-1354604
Erratum
Teriflunomide for the Treatment of Multiple Sclerosis
Further Information
Publication History
Publication Date:
21 September 2013 (online)
The publisher regrets an error in in the above article in Seminars in Neurology, Volume 33, Number 1, 2013, page 53, DOI:10.1055/s-0033-1343795. In the first paragraph, there is an error in the units given in the sentence, “Females who are taking teriflunomide with plans to conceive must undergo a cholestyramine or activated charcoal-based washout procedure after treatment discontinuation, and must confirm that the plasma level is at a level that presents minimal teratogenic risk (< 0.02 g/L) prior to conceiving.” The units should be “mg/L” rather than “g/L.”